The Structure of the Ternary Eg5-ADP-ispinesib Complex

Overview

Journal Acta Crystallogr D Biol Crystallogr

Specialty Chemistry

Date 2012 Sep 21

PMID 22993085

Citations 20

Authors

S K Talapatra

A W Schuttelkopf

F Kozielski

Affiliations

Soon will be listed here.

Abstract

The human kinesin Eg5 is responsible for bipolar spindle formation during early mitosis. Inhibition of Eg5 triggers the formation of monoastral spindles, leading to mitotic arrest that eventually causes apoptosis. There is increasing evidence that Eg5 constitutes a potential drug target for the development of cancer chemotherapeutics. The most advanced Eg5-targeting agent is ispinesib, which exhibits potent antitumour activity and is currently in multiple phase II clinical trials. In this study, the crystal structure of the Eg5 motor domain in complex with ispinesib, supported by kinetic and thermodynamic binding data, is reported. Ispinesib occupies the same induced-fit pocket in Eg5 as other allosteric inhibitors, making extensive hydrophobic interactions with the protein. The data for the Eg5-ADP-ispinesib complex suffered from pseudo-merohedral twinning and revealed translational noncrystallographic symmetry, leading to challenges in data processing, space-group assignment and structure solution as well as in refinement. These complications may explain the lack of available structural information for this important agent and its analogues. The present structure represents the best interpretation of these data based on extensive data-reduction, structure-solution and refinement trials.

Citing Articles

Mitotic Functions and Characters of KIF11 in Cancers.

Gao W, Lu J, Yang Z, Li E, Cao Y, Xie L Biomolecules. 2024; 14(4).

PMID: 38672404 PMC: 11047945. DOI: 10.3390/biom14040386.

Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC.

Indorato R, DeBonis S, Garcia-Saez I, Skoufias D Front Oncol. 2022; 12:965455.

PMID: 36313676 PMC: 9597087. DOI: 10.3389/fonc.2022.965455.

MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5.

Sebastian J, Raghav D, Rathinasamy K Mol Divers. 2022; 27(3):1203-1221.

PMID: 35789974 DOI: 10.1007/s11030-022-10482-w.

Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.

Murase Y, Ono H, Ogawa K, Yoshioka R, Ishikawa Y, Ueda H Cancer Sci. 2021; 112(11):4641-4654.

PMID: 34510663 PMC: 8586681. DOI: 10.1111/cas.15134.

Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.

Lomzik M, Hanif M, Budniok A, Blauz A, Makal A, Tchon D Inorg Chem. 2020; 59(20):14879-14890.

PMID: 33003697 PMC: 7584371. DOI: 10.1021/acs.inorgchem.0c00957.

References

Souid A, Dubowy R, Ingle A, Conlan M, Sun J, Blaney S . A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010; 55(7):1323-8. PMC: 3053384. DOI: 10.1002/pbc.22609. View

Mayer T, Kapoor T, Haggarty S, King R, Schreiber S, Mitchison T . Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286(5441):971-4. DOI: 10.1126/science.286.5441.971. View

Yeates T . Detecting and overcoming crystal twinning. Methods Enzymol. 1997; 276:344-58. View

Murshudov G, Skubak P, Lebedev A, Pannu N, Steiner R, Nicholls R . REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):355-67. PMC: 3069751. DOI: 10.1107/S0907444911001314. View

Cox C, Garbaccio R . Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. Anticancer Agents Med Chem. 2011; 10(9):697-712. DOI: 10.2174/187152010794479807. View

Sheth P, Basso A, Duca J, Lesburg C, Ogas P, Gray K . Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein. Biochemistry. 2009; 48(46):11045-55. DOI: 10.1021/bi900946r. View

Zhang B, Liu J, Xu Y, Ng S . Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity. Biochem Biophys Res Commun. 2008; 372(4):565-70. DOI: 10.1016/j.bbrc.2008.05.074. View

Turner J, Anderson R, Guo J, Beraud C, Fletterick R, Sakowicz R . Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J Biol Chem. 2001; 276(27):25496-502. DOI: 10.1074/jbc.M100395200. View

Lebedev A, Vagin A, Murshudov G . Intensity statistics in twinned crystals with examples from the PDB. Acta Crystallogr D Biol Crystallogr. 2005; 62(Pt 1):83-95. DOI: 10.1107/S0907444905036759. View

10.

Harrison M, Holen K, Liu G . Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol. 2009; 7(1):54-64. PMC: 2904974. View

11.

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

12.

Adams P, Grosse-Kunstleve R, Hung L, Ioerger T, McCoy A, Moriarty N . PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002; 58(Pt 11):1948-54. DOI: 10.1107/s0907444902016657. View

13.

Kabsch W . XDS. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):125-32. PMC: 2815665. DOI: 10.1107/S0907444909047337. View

14.

Holen K, Belani C, Wilding G, Ramalingam S, Volkman J, Ramanathan R . A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2010; 67(2):447-54. PMC: 4160065. DOI: 10.1007/s00280-010-1346-5. View

15.

Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser C . Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol. 2003; 335(2):547-54. DOI: 10.1016/j.jmb.2003.10.074. View

16.

Weil D, Garcon L, Harper M, Dumenil D, Dautry F, Kress M . Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques. 2002; 33(6):1244-8. DOI: 10.2144/02336st01. View

17.

Chen V, Arendall 3rd W, Headd J, Keedy D, Immormino R, Kapral G . MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):12-21. PMC: 2803126. DOI: 10.1107/S0907444909042073. View

18.

Lad L, Luo L, Carson J, Wood K, Hartman J, Copeland R . Mechanism of inhibition of human KSP by ispinesib. Biochemistry. 2008; 47(11):3576-85. DOI: 10.1021/bi702061g. View

19.

Vaguine A, RICHELLE J, Wodak S . SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 1):191-205. DOI: 10.1107/S0907444998006684. View

20.

Schuttelkopf A, van Aalten D . PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 8):1355-63. DOI: 10.1107/S0907444904011679. View